Transfusion‐associated circulatory overload—a systematic review of diagnostic biomarkers

Transfusion‐associated circulatory overload (TACO) is the leading cause of transfusion‐related major morbidity and mortality. Diagnosing TACO is difficult because there are no pathognomonic signs and symptoms. TACO biomarkers may aid in diagnosis, decrease time to treatment, and differentiate from other causes of posttransfusion dyspnea such a transfusion‐related acute lung injury.

[1]  L. Sokoll,et al.  N‐terminal pro‐brain natriuretic peptide is a useful diagnostic marker for transfusion‐associated circulatory overload , 2008, Transfusion.

[2]  D. Lloyd‐Jones,et al.  Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. , 2007, Journal of the American College of Cardiology.

[3]  E. Ruokonen,et al.  Predictive value of N-terminal pro–brain natriuretic peptide in severe sepsis and septic shock* , 2007, Critical care medicine.

[4]  S. Fu,et al.  Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure , 2018, Journal of Biological Engineering.

[5]  M. Popovsky,et al.  How we view and approach transfusion‐associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention , 2013, Transfusion.

[6]  T. Mueller,et al.  Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. , 2003, Clinical chemistry.

[7]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[8]  J. Steingrub,et al.  Hemotherapy bedside biovigilance involving vital sign values and characteristics of patients with suspected transfusion reactions associated with fluid challenges: can some cases of transfusion‐associated circulatory overload have proinflammatory aspects? , 2012, Transfusion.

[9]  S. Kleinman,et al.  Incidence and clinical characteristics of transfusion‐associated circulatory overload using an active surveillance algorithm , 2017, Vox sanguinis.

[10]  J. Callum,et al.  A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload. , 2013, Transfusion medicine reviews.

[11]  J. Callum,et al.  The association of fever with transfusion‐associated circulatory overload , 2017, Vox sanguinis.

[12]  C. Silliman,et al.  Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. , 2003, Blood.

[13]  M. Looney,et al.  Transfusion‐related acute lung injury in the paediatric patient: two case reports and a review of the literature , 2006, Transfusion medicine.

[14]  O. Gajic,et al.  Pulmonary edema after transfusion: How to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury , 2006, Critical care medicine.

[15]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[16]  Elizabeth Sykes,et al.  Analytical relationships among Biosite, Bayer, and Roche methods for BNP and NT-proBNP. , 2005, American journal of clinical pathology.

[17]  S. Réhman,et al.  Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. , 2008, Journal of the American College of Cardiology.

[18]  C. Lindsell,et al.  Galectin 3 complements BNP in risk stratification in acute heart failure , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[19]  M. Tomaniak,et al.  Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience. , 2016, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[20]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[21]  E. Shapiro,et al.  Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit , 2005 .

[22]  O. Gajic,et al.  The accuracy of natriuretic peptides (brain natriuretic peptide and N‐terminal pro‐brain natriuretic) in the differentiation between transfusion‐related acute lung injury and transfusion‐related circulatory overload in the critically ill , 2009, Transfusion.

[23]  A. Wu,et al.  Transfusion‐related acute lung injury and transfusion‐associated circulatory overload: mutually exclusive or coexisting entities? , 2007, Transfusion.

[24]  J. Binnekade,et al.  The practice of diagnosing and reporting transfusion‐associated circulatory overload: a national survey among physicians and haemovigilance officers , 2018, Transfusion medicine.

[25]  M. Shlipak,et al.  Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study , 2006, Circulation.

[26]  E. Murphy,et al.  Transfusion-associated circulatory overload (TACO): prevention, management, and patient outcomes , 2015 .

[27]  G. Hillis,et al.  B‐Type natriuretic peptide and the prediction of outcome in patients admitted to intensive care , 2005, Anaesthesia.

[28]  E. Murphy,et al.  Differentiating pulmonary transfusion reactions using recipient and transfusion factors , 2017, Transfusion.

[29]  F. Maupas-Schwalm,et al.  Head-to-head comparison of 10 natriuretic peptide assays , 2015, Clinical chemistry and laboratory medicine.

[30]  J. Raval,et al.  Passive reporting greatly underestimates the rate of transfusion‐associated circulatory overload after platelet transfusion , 2015, Vox sanguinis.

[31]  N. Juffermans,et al.  Transfusion-related acute lung injury: a clinical review , 2013, The Lancet.

[32]  R. Skeate,et al.  Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload , 2007, Current opinion in hematology.

[33]  E. Massey,et al.  Guideline on the investigation and management of acute transfusion reactions Prepared by the BCSH Blood Transfusion Task Force , 2012, British journal of haematology.

[34]  M. Alpert,et al.  Short-term fluctuations of plasma NT-proBNP levels in patients with new-onset atrial fibrillation: a way to assess time of onset? , 2010, Heart.

[35]  A. Maisel,et al.  Role of Cardiac Troponin Levels in Acute Heart Failure. , 2015, Cardiac failure review.

[36]  E. Murphy,et al.  Cytokines and clinical predictors in distinguishing pulmonary transfusion reactions , 2015, Transfusion.

[37]  Anan Huang,et al.  Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction , 2018, Acta cardiologica.

[38]  A. Maisel,et al.  Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure , 2016, Arquivos brasileiros de cardiologia.

[39]  C. Passino,et al.  Systematic differences between BNP immunoassays: comparison of methods using standard protocols and quality control materials. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[40]  Y. Kihara,et al.  B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. , 2006, Journal of the American College of Cardiology.

[41]  P. Ponikowski,et al.  Growth differentiation factor 15 (GDF‐15) in patients admitted for acute heart failure: results from the RELAX‐AHF study , 2015, European journal of heart failure.

[42]  M. Matthay,et al.  Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. , 2001, American journal of respiratory and critical care medicine.

[43]  M. Looney,et al.  Reducing Noninfectious Risks of Blood Transfusion , 2011, Anesthesiology.

[44]  L. Lenert,et al.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.

[45]  D. Talmor,et al.  Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. , 2007, Chest.

[46]  U. Sachs,et al.  Pulmonary Transfusion Reactions , 2008, Transfusion Medicine and Hemotherapy.

[47]  W. Seeger,et al.  Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. , 1996, The European respiratory journal.

[48]  M. Levi,et al.  Transfusion-related acute lung injury in cardiac surgery patients is characterized by pulmonary inflammation and coagulopathy: A prospective nested case-control study* , 2012, Critical care medicine.

[49]  D. Giacherio,et al.  Use of B‐natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion‐associated circulatory overload , 2005, Transfusion.

[50]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[51]  Analytical Relationships Among Biosite, Bayer, and Roche Methods for BNP and NT-proBNP , 2005 .

[52]  O. Hammarsten,et al.  Prognostic values of NTpro BNP/BNP ratio in comparison with NTpro BNP or BNP alone in elderly patients with chronic heart failure in a 2-year follow up. , 2012, International journal of cardiology.

[53]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[54]  E. Zwang,et al.  Vitamin K‐dependent coagulation factors and fibrinogen levels in FFP remain stable upon repeated freezing and thawing , 2003, Transfusion.

[55]  Claudio Passino,et al.  State of the art of immunoassay methods for B-type natriuretic peptides: An update , 2015, Critical reviews in clinical laboratory sciences.

[56]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[57]  H. Nakazawa,et al.  Impact of immunoreactive substances contained in apheresis platelet concentrate on postoperative respiratory function in surgical patients receiving platelet transfusion: a prospective cohort study , 2013, Transfusion medicine.